Silo Pharma Advances Alzheimer's Treatment with New Patent Application for SPC-14

Silo Pharma (NASDAQ: SILO) has taken a significant step in the fight against Alzheimer's disease by filing a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal compound. This compound, exclusively licensed from Columbia University, targets cognitive and neuropsychiatric symptoms associated with Alzheimer's, focusing on the glutamate receptor NDMAR and serotonin 5-HT4. Preclinical studies have shown that SPC-14 could potentially improve cognitive memory function, offering hope for a condition that affects millions worldwide.

The patent filing is part of Silo Pharma's broader intellectual property strategy aimed at protecting its innovative drug platforms. The company is at the forefront of developing novel therapeutics for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Silo Pharma's approach combines traditional therapies with psychedelic treatments in novel formulations and drug-delivery systems, positioning it as a leader in the biopharmaceutical sector.

Among Silo Pharma's pipeline, SPC-14 stands out for its potential to address a critical unmet need in Alzheimer's treatment. The company's commitment to research and development, through collaborations with universities and independent laboratories, underscores its dedication to advancing medical science. This patent application not only highlights Silo Pharma's innovative capabilities but also its potential to make a lasting impact on the cannabis and psychedelic industries by bringing new, effective treatments to market.

For more information on Silo Pharma's developments, visit https://ibn.fm/UioG3.